Literature DB >> 10884427

Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

P Chames1, S E Hufton, P G Coulie, B Uchanska-Ziegler, H R Hoogenboom.   

Abstract

Antitumor antibodies with the same specificity as cytotoxic T lymphocytes that recognize antigenic peptides encoded by tumor-associated genes and presented by MHC class I molecules would be valuable tools to analyze the antigenicity or target tumor cells in vivo. To obtain a human antibody directed against a peptide encoded by gene melanoma-associated antigen (MAGE)-A1 and presented by HLA-A1 molecules, we selected a large phage Fab antibody repertoire on a recombinant version of the complex HLA-A1-MAGE-A1 produced by in vitro refolding. One of the selected phage antibodies shows binding to HLA-A1 complexed with the MAGE-A1 peptide, but does not show binding to HLA-A1 complexed with a peptide encoded by gene MAGE-A3 and differing from the MAGE-A1 peptide by only three residues. Phages carrying this recombinant antibody bind to HLA-A1(+) cells only after in vitro loading with MAGE-A1 peptide. These results indicate that nonimmunized phage Fab libraries are a source of antibodies with a T cell antigen receptor-like specificity. The human anti-HLA-A1-MAGE-A1 antibody described here may prove very useful for monitoring the cell surface expression of these complexes, and eventually, as a targeting reagent for the specific immunotherapy of HLA-A1 patients bearing a MAGE-A1-positive tumor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884427      PMCID: PMC16654          DOI: 10.1073/pnas.97.14.7969

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  The monoclonal antibody HCA2 recognises a broadly shared epitope on selected classical as well as several non-classical HLA class I molecules.

Authors:  C Seitz; B Uchanska-Ziegler; A Zank; A Ziegler
Journal:  Mol Immunol       Date:  1998-09       Impact factor: 4.407

2.  Modulation of the immune response in multiple sclerosis: production of monoclonal antibodies specific to HLA/myelin basic protein.

Authors:  J Puri; R Arnon; E Gurevich; D Teitelbaum
Journal:  J Immunol       Date:  1997-03-01       Impact factor: 5.422

3.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.

Authors:  M Marchand; N van Baren; P Weynants; V Brichard; B Dréno; M H Tessier; E Rankin; G Parmiani; F Arienti; Y Humblet; A Bourlond; R Vanwijck; D Liénard; M Beauduin; P Y Dietrich; V Russo; J Kerger; G Masucci; E Jäger; J De Greve; J Atzpodien; F Brasseur; P G Coulie; P van der Bruggen; T Boon
Journal:  Int J Cancer       Date:  1999-01-18       Impact factor: 7.396

4.  A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

Authors:  P S Andersen; A Stryhn; B E Hansen; L Fugger; J Engberg; S Buus
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

5.  Production, crystallization, and preliminary X-ray analysis of the human MHC class Ib molecule HLA-E.

Authors:  C A O'Callaghan; J Tormo; B E Willcox; C D Blundell; B K Jakobsen; D I Stuart; A J McMichael; J I Bell; E Y Jones
Journal:  Protein Sci       Date:  1998-05       Impact factor: 6.725

Review 6.  Immunocytokines: a new approach to immunotherapy of melanoma.

Authors:  R A Reisfeld; J C Becker; S D Gillies
Journal:  Melanoma Res       Date:  1997-08       Impact factor: 3.599

7.  Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.

Authors:  P Henderikx; M Kandilogiannaki; C Petrarca; S von Mensdorff-Pouilly; J H Hilgers; E Krambovitis; J W Arends; H R Hoogenboom
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

8.  Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.

Authors:  U Altenschmidt; R Kahl; D Moritz; B S Schnierle; B Gerstmayer; W Wels; B Groner
Journal:  Clin Cancer Res       Date:  1996-06       Impact factor: 12.531

9.  Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.

Authors:  B Seliger; A Höhne; A Knuth; H Bernhard; B Ehring; R Tampé; C Huber
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

10.  beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

Authors:  D J Hicklin; Z Wang; F Arienti; L Rivoltini; G Parmiani; S Ferrone
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

View more
  26 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 2.  Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.

Authors:  J M Boulter; B K Jakobsen
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  Epitopes of the class I major histocompatibility complex (MHC-I) recognized in the syngeneic or allogeneic context predominantly linked to antigenic peptide loading to its binding groove.

Authors:  P Nguyen van Binh; H T Duc
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

4.  Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Authors:  Eynav Klechevsky; Michael Gallegos; Galit Denkberg; Karolina Palucka; Jacques Banchereau; Cyril Cohen; Yoram Reiter
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 5.  TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.

Authors:  Jon A Weidanz; Oriana Hawkins; Bhavna Verma; William H Hildebrand
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

6.  An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Authors:  Anna Sergeeva; Gheath Alatrash; Hong He; Kathryn Ruisaard; Sijie Lu; James Wygant; Bradley W McIntyre; Qing Ma; Dan Li; Lisa St John; Karen Clise-Dwyer; Jeffrey J Molldrem
Journal:  Blood       Date:  2011-02-04       Impact factor: 22.113

7.  Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity.

Authors:  Pravin Kumar; Ardeschir Vahedi-Faridi; Wolfram Saenger; Andreas Ziegler; Barbara Uchanska-Ziegler
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

8.  Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Authors:  Tao Dao; Su Yan; Nicholas Veomett; Dmitry Pankov; Liang Zhou; Tatyana Korontsvit; Andrew Scott; Joseph Whitten; Peter Maslak; Emily Casey; Taochao Tan; Hong Liu; Victoria Zakhaleva; Michael Curcio; Ekaterina Doubrovina; Richard J O'Reilly; Cheng Liu; David A Scheinberg
Journal:  Sci Transl Med       Date:  2013-03-13       Impact factor: 17.956

9.  Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.

Authors:  Galit Denkberg; Cyril J Cohen; Avital Lev; Patrick Chames; Hennie R Hoogenboom; Yoram Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

10.  Plasma Cells Are the Most Abundant Gluten Peptide MHC-expressing Cells in Inflamed Intestinal Tissues From Patients With Celiac Disease.

Authors:  Lene Støkken Høydahl; Lisa Richter; Rahel Frick; Omri Snir; Kristin Støen Gunnarsen; Ole J B Landsverk; Rasmus Iversen; Jeliazko R Jeliazkov; Jeffrey J Gray; Elin Bergseng; Stian Foss; Shuo-Wang Qiao; Knut E A Lundin; Jørgen Jahnsen; Frode L Jahnsen; Inger Sandlie; Ludvig M Sollid; Geir Åge Løset
Journal:  Gastroenterology       Date:  2018-12-26       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.